Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease
Controlled study in people · 2000
- What was studied
- Three groups: two Semax administration routes and a control; sample size not established here
- Main finding
- A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.
Reported findings and study design
A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.
Vascular, toxic-allergic, inflammatory and partial-atrophy optic-nerve conditions; intranasal, endonasal-electrophoresis and control groups.
Population or model Three groups: two Semax administration routes and a control; sample size not established here
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual outcomes | Reported improvement in acuity, total visual field, color vision and optic-nerve electrical measures | No effect size or arm counts supplied |
| Treatment comparison | 2 Semax delivery groups and 1 control group | All within a therapeutic package |
Route and combination-care effects cannot be separated from the abstract. This does not quantify visual benefit in a specific modern diagnosis.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Background treatment complicates attribution.
- Allocation, blinding and numerical treatment effects require full-text review.
Source details
Journal publication
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Sources checked
Citation
G S Polunin, S M Nurieva, D L Baiandin, N L Sheremet, L A Andreeva. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease Vestn Oftalmol. 116(1):15–18